# Table of Clinical Trials that use Response Adaptive Designs

| #  | Trial Name/ID | Status     | Phase     | General RA Method        | Sample Size    (final/planned)   | Number of Arms    | Outcome  | Condition                  | Primary Endpoint       | Notes | DOI | Year of Publication                                                                                                     |
|----|-----------------------------------------|------------|-----------|--------------------------|-----------------------------|----------------------------------|--------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------|-------|----------------------------------------------------------------------------------------------------------|------|
| 1  | ABT-089       |    completed        |    II        |       BRAR                   |        337                      | 7                                |      Ordinal                          |     Mild Alzheimer                        | Alzheimer’s Disease Assessment Scale, cognition subscale (ADAS-Cog) total score                         |  stoped early for futility     | [DOI link](https://doi.org/10.1097/WAD.0000000000000093)                                               | 2015 |
| 2  | Adverse Karyotype Acute Myeloid Leukemia   | completed    |            |     BRAR                     |     34                         | 3                                | Binary                        |          Leukemia                   | Complete remission without nonhematologic grade 4 toxicity by 50 days                                   |       | [DOI link](https://doi.org/10.1200/jco.2003.11.016)                                                    | 2003 |
| 3  | ADORE                              | completed  |  III | BRAR                     | 1100                         | 2                                | Binary                        | Preterm birth               | earliest preterm birth (<34 weeks) (ePTB)                                                              |       | [DOI link 1](https://doi.org/10.1186/s12884-017-1244-5), [DOI link 2](https://doi.org/10.1016/j.eclinm.2021.100905), [DOI link 3](https://doi.org/10.1080/10543406.2022.2148161) | 2017, 2021, 2022 |
| 4  | ARREST  / NCT03880565       |   completed         |     II      |           BRAR               |     30/176                         | 2                                | Survival                     |     refractory ventricular fibrillation/pulseless ventricular tachycardia out-of-hospital cardiac arrest                        | Number of patients who survived to hospital discharge                                                   |  Terminated early posterior probability of ECMO superiority exceeded the prespecified monitoring boundary. RAR never employed because first 30 patients randomised using ER. | [DOI link 1](https://doi.org/10.1016/j.ahj.2020.07.006), [DOI link 2](https://doi.org/10.1016%2FS0140-6736(20)32338-2) | 2020, 2020 |
| 5  | ASTIN                                   |  completed          |   II        |       BRAR                   |        966                      | 16                               |           Ordinal                   |     acute ischemic stroke                          | Change from baseline to day 90 on the Scandinavian Stroke Scale                                         |       | [DOI link](https://doi.org/10.1161/01.STR.0000092527.33910.89)                                         | 2003 |
| 6  | ATTACC / NCT04372589                                 |    completed        |     II/III      |     BRAR                     |    1200/3000                          | 2                                | Ordinal Categorical           |      Covid-19                       | Three possible outcomes based on the worst status of each patient through day 30                        |       | [DOI link](https://doi.org/10.1177/1740774520943846)                                                   | 2020 |
| 7  | AWARD-5  / NCT00734474    |   completed    |     III      |      BRAR  |     1202/1566      | 9         |       ordinal                          |     type 2 diabetes      | Clinical utility index (CUI) with possible values from 0 to 6                                           |       | [DOI link](https://doi.org/10.1111/dom.12305)                                                          | 2014 |
| 8  | BATTLE  / NCT00409968, NCT00411671, NCT00411632, NCT00410059, NCT00410189    |   completed    |    II       |          |       255                       | 4                                |     Binary         |      lung cancer          | 8-week disease control rate (DCR)                                                                      |       | [DOI link](https://doi.org/10.1158/2159-8274.CD-10-0010)                                         | 2011 |
| 9  | BATTLE-2   |   completed         |     II      |      -      |      186/200                        |         4                         |                Binary |            lung cancer                   |          8-week disease control rate (DCR)        |  Umbrella Trial incl. Biomarkers     | [DOI link](https://doi.org/10.1200/JCO.2015.66.0084)                                                   | 2016 |
| 10 | ESETT / NCT01960075  |   completed   |     III      |   BRAR    |             478/795                | 3                                | Binary                        |     Benzodiazepine-refractory status epilepticus    | Clinical cessation of status epilepticus                                                                |  Burn-In of 300 patients total     | [DOI link 1](https://doi.org/10.1111/epi.12288)   [DOI link 2](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30611-5/fulltext)                                                              | 2013, 2020 |
| 11 | endTB            |  completed          |   III        |       BRAR                   |       750                       | 6                                | Binary                        |        tuberculosis                     | Treatment success at 73 weeks after randomisation                                                       | BRAR for non-inferiority. Extensive simulation results.   | [DOI link 1](https://doi.org/10.1177/1740774516665090) [DOI link 2](https://link.springer.com/article/10.1186/s13063-021-05491-3) [DOI link 3](https://nejm.org/doi/full/10.1056/NEJMoa2400327)                                                  | 2016, 2021 |
| 12 | Fluoxetine | completed     |      | RPTW        | 89   | 2    | Ordinal  | Depressive Disorder                  | total of the first 17 items of the Hamilton Depression Scale (HAMD17)       |  | [DOI Link](https://doi.org/10.1080/01621459.1994.10476810) | 1993        |
| 13 | GBM AGILE / NCT03970447                               |      recruiting      |   seamless phase II/III        |        BRAR                  |              1030/550                | Multi-arm                        | Binary                        |      Glioblastoma                       | Overall survival                                                                                        |       | [DOI link](https://doi.org/10.1158/1078-0432.CCR-17-0764)                                      | 2018 |
| 14 | Gemcitabine for Metastatic Soft Tissue Sarcomas / NCT00142571| completed | II | BRAR | 122 | 2 |  | Metastatic Soft Tissue Sarcomas | tumor response (complete or partial response or stable disease lasting at least 24 weeks) |  | [DOI Link](https://doi.org/10.1200/JCO.2006.10.4117) | 2007 |
| 15 | Ghrelin Agonist TZP-101                 |    completed        |    II b       |                          |        236                      | 8                                | Time-to-Event                 |        Postoperative Ileus After Partial Colectomy                     | Time to first bowel movement                                                                           |       | [DOI link](https://doi.org/10.1007%2FDCR.0b013e3181b54166)                                             | 2010 |
| 16 | ICECAP / NCT04217551| recruiting     |   not applicable   | BRAR        | 1800   | 20    | Ordinal  | Neuroprotection after cardiac arrest     | weighted modified Rankin Scale (mRS)       | mRS is a measure of neurologic disability | [DOI Link](https://doi.org/10.21203/rs.3.rs-4033108/v1) | 2024 |
| 17 | I-SPY 2                                 |    completed     |     II & III     |      BRAR                    |             272                 | Multi-arm  (many treatment combinations)                      |        |   Breast Cancer     | Pathologic complete response (pCR)                             |    Biomarkers, Dropping arms when Bayesian probability below a threshold   | [DOI link 1](https://doi.org/10.1038/clpt.2009.68), [DOI link 2](https://doi.org/10.1056/NEJMoa1513749), [DOI link 3](https://doi.org/10.1056/NEJMoa1513750) | 2009, 2016, 2016 |
| 18 | Insulin sliding scale vs weight-based regimen |            |           |     BRAR                     |                              | 3                                | Continuous                    |                             | Hospital length of stay                                                                                |   Tuned BRAR with Bayesian stopping rule   | [DOI link](https://doi.org/10.1177%2F1740774511398368)                                                 | 2011 |
| 19 | Ketamine in LL-TRD                      |    completed        |    II       |    BRAR        |            33                  | 5                                |                                |     late-life treatment-resistant depression         | Treatment response 50% improvement on depression rating scale                                           |       | [DOI link 1](https://doi.org/10.1016/j.conctc.2019.100432), [DOI link 2](https://doi.org/10.1038/s41386-021-01242-9)                                              | 2019, 2021 |
| 20 | Leborexant / NCT01995838 |      completed      |     II      |              BRAR            |          291/300                    | 7                                |                               |             insomnia                | Utility function integrating sleep efficiency and safety |       | [DOI link](https://doi.org/10.5664/jcsm.6800)                                                          | 2017 |
| 21 | MOTIVATE-C / ACTRN12623000024640 | recruiting     |  not applicable  | BRAR        | 1300   | 21    |   | Hepatitis-C                  | Initiation of Direct-acting antiviral (DAA) therapy for hepatitis C infection       |  | [DOI Link](https://doi.org/10.1186/s13063-024-08212-8) | 2024 |
| 22 | PAIN-CONTRoLS / NCT02260388     | completed           |    III       |          BRAR                |       402        | 4                                |   Discrete                    |     cryptogenic sensory polyneuropathy (CSPN)                         | Combination of two endpoints: at least 50% pain reduction in Likert scale AND observed percentage of patients who quit   |  Burn-in of 20 patients per arm     | [DOI link 1](https://doi.org/10.1186/s13063-016-1544-5), [DOI link 2](https://doi.org/10.1001/jamaneurol.2020.2590), [DOI link 3](https://doi.org/10.1016/j.conctc.2023.101220) | 2016, 2020, 2023 |  
| 23 | RACE                     |   completed         |     II      |         BRAR       |         250                     | 4                                |  Discrete     |       Septic Shock                      |            Sequential organ failure assessment score at 48 hours from enrolment                          |       | [DOI link](https://doi.org/10.1001/jamanetworkopen.2018.6076)                                          | 2018 |
| 24 | REMAP-CAP   / NCT02735707          |      recruiting      |     III      |       BRAR                   |         flexible                     | 16 domains, 56 arms in total     | Binary                        |                             | 90-day mortality                                                                                        |       | [DOI link](https://doi.org/10.1513/AnnalsATS.202003-192SD)                                             | 2020 |
| 25 | SHINE / NCT01369069 | completed | III | BRAR | 1151/1400 | 2 |  | acute ischemic stroke patients | number of patients with a favourable modified Rankin scale |  | [DOI link 1](https://doi.org/10.1111/ijs.12045), [DOI link 2](https://doi.org/10.1186/s13063-015-0574-8) | 2014, 2015 |
| 26 | SPRINT       |    completed        |   II    |    BRAR   |        176            | 6     |       Discrete                         |   painful lumbosacral radiculopathy   | Change from baseline in the mean 24-hour average general pain intensity (AGPI) score                    |       | [DOI link](https://doi.org/10.1097/j.pain.0000000000000983)                                            | 2017 |
| 27 | StratosPHere 2                       |      recruiting      |    II       |    BRAR       |             40                 | 3                                |  |         Pulmonary arterial hypertension                    |    Target engagement (individual changes in 8 genes from baseline to follow-up)  |      | [DOI link 1](https://doi.org/10.1186/s13063-024-08485-z)       | 2024 |
| 28 | STURDY  /  NCT02166333  |      terminated      |   II        |   BRAR   |      688/1200                        | 4        | Time-to-Event     |                             | Time to first fall or death (whichever comes first)    |   vitamin D supplementation for fall prevention in older adults    | [DOI link](https://doi.org/10.1016/j.cct.2018.08.004)                                                  | 2018 |
| 29 | tobacco cessation                       |     completed       |    III       |    BRAR       |     739                         | 2                                | Binary |         Smoking                    | Biochemically verified abstinence       |      | [DOI link 1](https://doi.org/10.1186/s13063-017-2119-9), [DOI link 2](https://doi.org/10.1001/jamainternmed.2022.7170)                                                 | 2017, 2023 |
|30| Safety of Enoxaparin vs. Dextran-70 | completed|- | PTW| 327| 2 | Binary |  patients undergoing digestive surgery | Excessive bleeding (composite) | | [DOI link](https://doi.org/10.3109/00365529309098302) | 1993 |
|30| Safety of Enoxaparin vs. Dextran-70 | completed|- | PTW| 327| 2 | Binary |  patients undergoing digestive surgery | Excessive bleeding (composite) | | [DOI link](https://doi.org/10.3109/00365529309098302) | 1993 |
